[Gastric cancer genome profiling reveals HER2 false-negative status and informs a successful trastuzumab treatment strategy].
Nihon Shokakibyo Gakkai Zasshi
; 119(10): 937-945, 2022.
Article
em Ja
| MEDLINE
| ID: mdl-36216544
ABSTRACT
Intratumoral HER2 heterogeneity is a well-described gastric cancer feature and may explain many false-negative results related to this oncogene. An 81-year-old man was diagnosed at our hospital with stage IV gastric cancer with multiple lymph node metastases. Immunohistochemistry (IHC) analysis indicated that the primary tumor was HER2-negative. After a chemotherapy course, we submitted a pretreatment biopsy specimen for comprehensive cancer genome profiling (CGP) to determine the last-line therapy. This revealed HER2 amplification. The specimen was reevaluated using fluorescence in situ hybridization and IHC with deeper-cut specimens, which confirmed that the tumor was indeed HER2-positive. Therefore, the patient was treated with chemotherapy plus trastuzumab, which elicited tumor shrinkage and conferred long-term survival. Our current data underscore the CGP importance, which can provide more accurate tumor profilings and inform subsequent treatment decisions.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
Tipo de estudo:
Prognostic_studies
Limite:
Aged80
/
Humans
/
Male
Idioma:
Ja
Ano de publicação:
2022
Tipo de documento:
Article